Approval · Notice of Compliance 3816 · 1997
LESCOL: Notice of Compliance 3816
Issued August 13, 1997
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 3816
- Date
- August 13, 1997
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Therapeutic class
- Lipid metabolism regulator
Products in this notice
Medicinal ingredients
- FLUVASTATIN SODIUM 20 MG per CAP
- FLUVASTATIN SODIUM 40 MG per CAP